You are here

Overview

Cancer Research UK’s Commercial Partnerships team, a component of the Research and Innovation division, develops promising ideas into successful cancer therapeutics, vaccines, diagnostics and enabling technologies. We are dedicated to advancing discoveries to beat cancer by developing and commercialising exciting new discoveries in cancer research. Our deep understanding of both academia and industry enables us to translate promising research into commercial propositions to deliver patient benefit and commercial value that will support further cancer research.

Cancer Research UK, through its subsidiary Cancer Research Technology Ltd, has exclusive rights to more than £350m of world-class cancer research annually. As funders of much of the exciting science happening in the UK and beyond today, we offer unique opportunities to commercial partners looking for early involvement in new discoveries.


  • We have exclusive rights to £350 million of cancer research per year.
  • Last year we leveraged £20 million in industry funding to progress promising cancer research.
  • Cancer Research UK’s world-class scientists have contributed to over 20,000 academic publications to date.
  • Our portfolio contains over 200 projects available for licensing and co-development.
  • A proven track record of successful innovation stems from 30 years’ specialist experience in the commercialisation of cancer research.
  • We currently have more than 30 partnered agents in pre-clinical and clinical development, and 5 drugs already on the market and benefiting patients.
  • To date, CRUK-TDL has established 6 major industry partnerships with AstraZeneca, Teva, FORMA, Merck, MRCT and Artios.

 

  • Our US Office

    Cancer Research UK is based in the UK but we’re not just UK focused. We also operate a US subsidiary, which forms an extension of our Commercial Partnerships team. They are based in Cambridge, Massachusetts; a major hub for life-science organisations and a centre of academic excellence. It is headed up by Dr Andrea Schievella, who has been focussed on partnering early stage life sciences technologies for over 15 years.  

  • CRUK-TDL

    CRUK Therapeutic Discovery Laboratories (CRUK-TDL) is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, their expertise spans cancer target validation and disease positioning, assay development and high throughput screening, protein crystallography, medicinal chemistry, PK-PD and cancer models.

    CRUK-TDL brings together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and their in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients.

     

  • RESEARCH TOOLS

    Ximbio is a website created to enable the sharing of research tools within the global life science community. Research reagents, such as antibodies, mice and cell lines are the cornerstones of basic scientific research; without them, scientists could not test their hypotheses, validate their ideas or develop new concepts. Ximbio acts a marketplace for scientists to maximise commercial opportunities for these tools and share information. Ximbio aims to unify the life science community by making research tools widely available and accelerate research.

  • CDP

    The Clinical Development Partnerships (CDP) scheme aims to increase the number of new treatments for cancer patients by taking more novel oncology agents into clinical development. CDP brings promising anti-cancer agents, which companies are otherwise unable to develop, into clinical trials.

    CDP offers companies an alternative path for clinical development. It provides a unique opportunity to work with us, and enables companies to realise the full potential of their oncology pipelines for the benefit of people with cancer. We are looking to partner with leading pharmaceutical and biotechnology companies who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Our US Office Open

Cancer Research UK is based in the UK but we’re not just UK focused. We also operate a US subsidiary, which forms an extension of our Commercial Partnerships team. They are based in Cambridge, Massachusetts; a major hub for life-science organisations and a centre of academic excellence. It is headed up by Dr Andrea Schievella, who has been focussed on partnering early stage life sciences technologies for over 15 years.  

Related links

CRUK-TDL Open

CRUK Therapeutic Discovery Laboratories (CRUK-TDL) is the in-house CRUK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, their expertise spans cancer target validation and disease positioning, assay development and high throughput screening, protein crystallography, medicinal chemistry, PK-PD and cancer models.

CRUK-TDL brings together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and their in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients.

 

Related links

RESEARCH TOOLS Open

Ximbio is a website created to enable the sharing of research tools within the global life science community. Research reagents, such as antibodies, mice and cell lines are the cornerstones of basic scientific research; without them, scientists could not test their hypotheses, validate their ideas or develop new concepts. Ximbio acts a marketplace for scientists to maximise commercial opportunities for these tools and share information. Ximbio aims to unify the life science community by making research tools widely available and accelerate research.

Related links

CDP Open

The Clinical Development Partnerships (CDP) scheme aims to increase the number of new treatments for cancer patients by taking more novel oncology agents into clinical development. CDP brings promising anti-cancer agents, which companies are otherwise unable to develop, into clinical trials.

CDP offers companies an alternative path for clinical development. It provides a unique opportunity to work with us, and enables companies to realise the full potential of their oncology pipelines for the benefit of people with cancer. We are looking to partner with leading pharmaceutical and biotechnology companies who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Related links